Featured Research

from universities, journals, and other organizations

Atrogin Breaks Down The Side Effects Of Statins

Date:
November 12, 2007
Source:
Journal of Clinical Investigation
Summary:
Statins are a popular class of drugs used to successfully combat high cholesterol. However, the rare, but serious, and poorly understood side effect of skeletal muscle breakdown prevents more prevalent use of these drugs. New research in mice has now indicated that atrogin-1 is a critical mediator of statin-induced muscle damage and that inhibiting atrogin-1 function might protect against this unwanted side effect of statins.

Statins are a popular class of drugs used to successfully combat high cholesterol.

However, the rare, but serious, and poorly understood side effect of skeletal muscle breakdown (a process known as atrophy) prevents more prevalent use of these drugs.

New insight into the mechanism of statin-induced skeletal muscle atrophy has been provided by researchers at Beth Israel Deaconess Medical Center, Boston.

In this study, the authors focused on the activity of atrogin-1, a gene highly associated with skeletal muscle atrophy. Following treatment with lovastatin, a commonly prescribed statin, atrogin-1 was induced in cultured mouse muscle cells and in zebrafish embryos.

Furthermore, statin-induced muscle injury in the zebrafish was prevented by reducing the amount of atrogin-1 expressed. Finally, when the protein PGC-1a (which protects against skeletal muscle damage and atrophy) was expressed in zebrafish, both atrogin-1 expression and lovastatin-induced muscle damage were prevented.

These data led the authors to conclude that atrogin-1 is a critical mediator of statin-induced muscle damage and that inhibiting atrogin-1 function might protect against this unwanted side effect of statins.

Article: The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity, Journal of Clinical Investigation


Story Source:

The above story is based on materials provided by Journal of Clinical Investigation. Note: Materials may be edited for content and length.


Cite This Page:

Journal of Clinical Investigation. "Atrogin Breaks Down The Side Effects Of Statins." ScienceDaily. ScienceDaily, 12 November 2007. <www.sciencedaily.com/releases/2007/11/071109091531.htm>.
Journal of Clinical Investigation. (2007, November 12). Atrogin Breaks Down The Side Effects Of Statins. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2007/11/071109091531.htm
Journal of Clinical Investigation. "Atrogin Breaks Down The Side Effects Of Statins." ScienceDaily. www.sciencedaily.com/releases/2007/11/071109091531.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins